Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Non-Current Assets (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Other Non-Current Assets readings, the most recent being $890000.0 for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets fell 68.71% to $890000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $890000.0, a 68.71% decrease, with the full-year FY2025 number at $886000.0, down 71.45% from a year prior.
  • Other Non-Current Assets hit $890000.0 in Q1 2026 for Atara Biotherapeutics, roughly flat from $886000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $51.4 million in Q1 2022 to a low of $881000.0 in Q3 2025.
  • Median Other Non-Current Assets over the past 5 years was $3.7 million (2024), compared with a mean of $6.9 million.
  • Biggest five-year swings in Other Non-Current Assets: surged 196.49% in 2022 and later tumbled 86.57% in 2023.
  • Atara Biotherapeutics' Other Non-Current Assets stood at $7.0 million in 2022, then crashed by 30.98% to $4.8 million in 2023, then tumbled by 35.94% to $3.1 million in 2024, then tumbled by 71.45% to $886000.0 in 2025, then rose by 0.45% to $890000.0 in 2026.
  • The last three reported values for Other Non-Current Assets were $890000.0 (Q1 2026), $886000.0 (Q4 2025), and $881000.0 (Q3 2025) per Business Quant data.